Compounds > rosiglitazone
Page last updated: 2024-08-25

rosiglitazone and mcc-555

rosiglitazone has been researched along with mcc-555 in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's5 (83.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kadowaki, T1
Brüne, B; Loitsch, S; Stein, J; Ulrich, S; von Knethen, A; Wächtershäuser, A1
Lazarenko, OP; Lecka-Czernik, B; Rzonca, SO; Suva, LJ1
Blay, J; Richard, CL1
Giaginis, C; Theocharis, S; Tsantili-Kakoulidou, A1
Flier, JS; Gardner, NP; Guan, HP; Kershaw, EE; Lazar, MA; Schupp, M1

Reviews

1 review(s) available for rosiglitazone and mcc-555

ArticleYear
[Insulin-sensitizing agents].
    Nihon rinsho. Japanese journal of clinical medicine, 1999, Volume: 57, Issue:3

    Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Humans; Hypoglycemic Agents; Isoxazoles; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones

1999

Other Studies

5 other study(ies) available for rosiglitazone and mcc-555

ArticleYear
Activation of PPARgamma is not involved in butyrate-induced epithelial cell differentiation.
    Experimental cell research, 2005, Oct-15, Volume: 310, Issue:1

    Topics: Alkaline Phosphatase; Apoptosis; Butyrates; Caco-2 Cells; Cell Cycle Proteins; Cell Differentiation; Cell Proliferation; Colonic Neoplasms; Epithelial Cells; Humans; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones

2005
Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat.
    Bone, 2006, Volume: 38, Issue:1

    Topics: Adipocytes; Animals; Bone Density; Bone Marrow Cells; Cell Culture Techniques; Cell Differentiation; Cell Line; Culture Media; Dose-Response Relationship, Drug; Gene Expression Regulation; Genetic Markers; Ligands; Male; Mice; Mice, Inbred C57BL; Osteoblasts; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazoles; Thiazolidinediones; Tomography, X-Ray Computed

2006
Thiazolidinedione drugs down-regulate CXCR4 expression on human colorectal cancer cells in a peroxisome proliferator activated receptor gamma-dependent manner.
    International journal of oncology, 2007, Volume: 30, Issue:5

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Membrane; Colorectal Neoplasms; Dose-Response Relationship, Drug; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Pioglitazone; PPAR gamma; Receptors, CXCR4; Rosiglitazone; Thiazolidinediones

2007
Investigation of the lipophilic behaviour of some thiazolidinediones. Relationships with PPAR-gamma activity.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2007, Oct-01, Volume: 857, Issue:2

    Topics: Chromans; Chromatography, High Pressure Liquid; Hydrogen-Ion Concentration; Lipids; Membranes, Artificial; Octanols; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transcriptional Activation; Troglitazone; Water

2007
PPARgamma regulates adipose triglyceride lipase in adipocytes in vitro and in vivo.
    American journal of physiology. Endocrinology and metabolism, 2007, Volume: 293, Issue:6

    Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue, Brown; Adipose Tissue, White; Anilides; Animals; Carboxylic Ester Hydrolases; Cycloheximide; Dietary Fats; Dose-Response Relationship, Drug; Fluorenes; Gene Expression; Leptin; Lipase; Membrane Proteins; Mice; Mice, Inbred Strains; Mice, Knockout; PPAR gamma; Prostaglandin D2; Protein Biosynthesis; RNA, Messenger; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones

2007